Is the benefit of sodium-glucose cotransporter inhibitors over heart failure progression on the kidney side?

References

1. • Vallon V.
   • Mü Hlbauer B.E.
   • Osswald H.
   Adenosine and kidney function.
   Physiol Rev. 2006; 86: 901-940
   10.1152/physrev.00031.2005
   View in Article

   • Google Scholar
2. • Thomson S.C.
   • Vallon V.
   Renal Effects of sodium-glucose co- transporter inhibitors.
   Am J Cardiol. 2019; 124: 28-35https://doi.org/10.1007/s00125-016-4157-3
   View in Article

   • Google Scholar
3. • Hansell P.
   • Welch W.J.
   • Blantz R.C.
   Palm F Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension.
   Clin Exp Pharmacol Physiol. 2013; 40: 123-137https://doi.org/10.1111/1440-1681.12034
   View in Article

   • Google Scholar
4. • McMurray J.J.V.
   • Solomon S.D.
   • Inzucchi S.E.
   • Køber L.
   • Kosiborod M.N.
   • Martinez F.A.
   • Ponikowski P.
   • Sabatine M.S.
   • Anand I.S.
   • Bělohlávek J.
   • Böhm M.
   • Chiang C.E.
   • Chopra V.K.
   • de Boer R.A.
   • Desai A.S.
   • Diez M.
   • Drozdz J.
   • Dukát A.
   • Ge J.
   • Howlett J.G.
   • Katova T.
   • Kitakaze M.
   • Ljungman C.E.A.
   • Merkely B.
   • Nicolau J.C.
   • O'Meara E.
   • Petrie M.C.
   • Vinh P.N.
   • Schou M.
   • Tereshchenko S.
   • Verma S.
   • Held C.
   • DeMets D.L.
   • Docherty K.F.
   • Jhund P.S.
   • Bengtsson O.
   • Sjöstrand M.
   • Langkilde A.M.
   DAPA-HF Trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction.
   N Engl J Med. 2019; 381: 1995-2008https://doi.org/10.1056/NEJMoa1911303
   View in Article

   • Google Scholar
5. • Packer M.
   • Anker S.D.
   • Butler J.
   • Filippatos G.
   • Pocock S.J.
   • Carson P.
   • Januzzi J.
   • Verma S.
   • Tsutsui H.
   • Brueckmann M.
   • Jamal W.
   • Kimura K.
   • Schnee J.
   • Zeller C.
   • Cotton D.
   • Bocchi E.
   • Böhm M.
   • Choi D.J.
   • Chopra V.
   • Chuquiure E.
   • Giannetti N.
   • Janssens S.
   • Zhang J.
   • JR Gonzalez Juanatey
   • Kaul S.
   • HP Brunner-La Rocca
   • Merkely B.
   • Nicholls S.J.
   • Perrone S.
   • Pina I.
   • Ponikowski P.
   • Sattar N.
   • Senni M.
   • Seronde M.F.
   • Spinar J.
   • Squire I.
   • Taddei S.
   • Wanner C.
   • Zannad F
   • EMPEROR-Reduced Trial Investigators
   Cardiovascular and renal outcomes with empagliflozin in heart failure.
   N Engl J Med. 2020; 383: 1413-1424https://doi.org/10.1056/NEJMoa2022190
   View in Article

   • Google Scholar
6. • Anker S.D.
   • Butler J.
   • Filippatos G.
   • Ferreira J.P.
   • Bocchi E.
   • Böhm M.
   • Brunner-La Rocca H.P.
   • Choi D.J.
   • Chopra V.
   • Chuquiure-Valenzuela E.
   • Giannetti N.
   • Gomez-Mesa J.E.
   • Janssens S.
   • Januzzi J.L.
   • Gonzalez-Juanatey J.R.
   • Merkely B.
   • Nicholls S.J.
   • Perrone S.V.
   • Piña I.L.
   • Ponikowski P.
   • Senni M.
   • Sim D.
   • Spinar J.
   • Squire I.
   • Taddei S.
   • Tsutsui H.
   • Verma S.
   • Vinereanu D.
   • Zhang J.
   • Carson P.
   • Lam C.S.P.
   • Marx N.
   • Zeller C.
   • Sattar N.
   • Jamal W.
   • Schnaidt S.
   • Schnee J.M.
   • Brueckmann M.
   • Pocock S.J.
   • Zannad F.
   • Packer M.
   EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction.
   N Engl J Med. 2021; 385: 1451-1461https://doi.org/10.1056/NEJMoa2107038
   View in Article

   • Google Scholar
7. • Berg D.D.
   • Jhund P.S.
   • Docherty K.F.
   • Murphy S.A.
   • Verma S.
   • Inzucchi S.E.
   • Køber L.
   • Kosiborod M.N.
   • Langkilde A.M.
   • Martinez F.A.
   • Bengtsson O.
   • Ponikowski P.
   • Sjöstrand M.
   • Solomon S.D.
   • McMurray J.J.V.
   • Sabatine M.S.
   Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction.
   JAMA Cardiol. 2021; 6: 499-507https://doi.org/10.1001/jamacardio.2020.7585
   View in Article

   • Google Scholar
8. • Jhund P.S.
   • Solomon S.D.
   • Docherty K.F.
   • Heerspink H.J.L.
   • Anand I.S.
   • Böhm M.
   • Chopra V.
   • de Boer R.A.
   • Desai A.S.
   • Ge J.
   • Kitakaze M.
   • Merkley B.
   • O'Meara E.
   • Shou M.
   • Tereshchenko S.
   • Verma S.
   • Vinh P.N.
   • Inzucchi S.E.
   • Køber L.
   • Kosiborod M.N.
   • Martinez F.A.
   • Ponikowski P.
   • Sabatine M.S.
   • Bengtsson O.
   • Langkilde A.M.
   • Sjöstrand M.
   • McMurray J.J.V.
   Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF.
   Circulation. 2021; 143: 298-309https://doi.org/10.1161/CIRCULATIONAHA.120.050391
   View in Article

   • Google Scholar
9. • Packer M.
   • Anker S.D.
   • Butler J.
   • Filippatos G.
   • Ferreira J.P.
   • Pocock S.J.
   • et al.
   for the EMPEROR-Reduced Trial Committees and Investigators, Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial, Eur Heart.
   J. 2021; 42: 671-680
   10.1093/eurheartj/ehaa968
   View in Article

   • Google Scholar
10. • Petersson M.
    • Friberg P.
    • Eisenhofer G.
    • Lambert G.
    • Rundqvist B.
    Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure.
    Eur Heart J. 2005; 26: 906-913https://doi.org/10.1093/eurheartj/ehi220
    View in Article

    • Google Scholar
11. • Khan M.S.
    • Bakris G.L.
    • Packer M.
    • Shahid I.
    • Anker S.D.
    • Fonarow G.C.
    • Wanner C.
    • Weir M.R.
    • Zannad F.
    • Butler J.
    Kidney function assessment and endpoint ascertainment in clinical trials.
    Eur Heart J. 2022; 43: 1379-1400https://doi.org/10.1093/eurheartj/ehab832
    View in Article

    • Google Scholar